XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Shen, Xiao Yong ^a   Lu, Fan Zhen ^a   Wu, Yun ^a   Zhao, Li Ting ^a   Lin, Zhi Feng ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; XRCC3 PROTEIN;

ADVANCED CANCER; ALLELE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; XRCC3 GENE;

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; PLATINUM; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 84881105218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069553     Document Type: Review

References (39)

1. Guilbert JJ, (2003) The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon) 16: 230.
2. Parkin DM, Pisani P, Ferlay J, (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
3. Jemal A, Thomas A, Murray T, Thun M, (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23-47.
4. Bahl A, Falk S, (2001) Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br J Cancer 84: 1143-1145.
5. Bosken CH, Wei Q, Amos CI, Spitz MR, (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94: 1091-1099.
6. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, et al. (2002) Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23: 295-299.
7. Zhou C, Ren S, Zhou S, Zhang L, Su C, et al. (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40: 954-960.
8. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27: 560-567.
9. Guo S, Li X, Gao M, Li Y, Song B, et al. (2013) The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One 8: e56213.
10. Kiyohara C, Takayama K, Nakanishi Y, (2010) Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis. J Nucleic Acids 2010: 701760.
11. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, et al. (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675.
12. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, et al. (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22: 1437-1445.
13. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, et al. (2012) Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7: 973-981.
14. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, et al. (2012) Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14: 207-213.
15. Provencio M, Camps C, Cobo M, De las Penas R, Massuti B, et al. (2012) Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol 70: 883-890.
16. Ke HG, Li J, Shen Y, You QS, Yan Y, et al. (2012) Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev 13: 4413-4416.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
19. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
20. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
21. Butkiewicz D, Drosik A, Suwinski R, Krzesniak M, Rusin M, et al. (2012) Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer 131: E1100-1108.
22. Yin M, Liao Z, Huang YJ, Liu Z, Yuan X, et al. (2011) Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One 6: e20055.
23. Liu L, Yuan P, Wu C, Zhang X, Wang F, et al. (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73: 110-115.
24. Sun X, Li F, Sun N, Shukui Q, Baoan C, et al. (2009) Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65: 230-236.
25. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, et al. (2007) Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13: 2876-2881.
26. Osawa K, Nakarai C, Uchino K, Yoshimura M, Tsubota N, et al. (2012) XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients. Int J Mol Sci 13: 16658-16667.
27. Xu C, Wang X, Zhang Y, Li L, (2011) Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14: 912-917.
28. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, et al. (2011) Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026.
29. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, et al. (2012) Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 118: 2466-2475.
30. Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, et al. (2011) Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 68: 1405-1412.
31. Ren S, Zhou S, Wu F, Zhang L, Li X, et al. (2012) Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75: 102-109.
32. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601.
33. Shellard SA, Fichtinger-Schepman AM, Lazo JS, Hill BT, (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500.
34. Au WW, Salama SA, Sierra-Torres CH, (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111: 1843-1850.
35. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, et al. (2013) ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 108: 1695-1703.
36. Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, et al. (2011) Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. J Thorac Oncol 6: 1320-1329.
37. Liu L, Wu J, Zhong R, Wu C, Zou L, et al. (2012) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog.
38. Liu L, Wu C, Wang Y, Zhong R, Duan S, et al. (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6: 1793-1800.
39. Wu J, Liu J, Zhou Y, Ying J, Zou H, et al. (2012) Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 18: 3972-3981.